CD38 and renal fibrosis: Taken together, these results indicate that targeting CD38 and NAD+ metabolism reduces kidney inflammation, partially by suppressing the infiltration of immune cells and NF-κB signaling, thus mitigating obstruction-induced renal fibrosis.